Growth hormone-releasing peptide 1
Also known as: Ala-His-D-βNal-Ala-Trp-D-Phe-Lys-NH2, GH-releasing peptide 1, GHRP-1, Growth hormone secretagogue‑1, Growth hormone‑releasing peptide‑1
Source Growth hormone-releasing peptide 1 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Synthetic hexapeptide (GHRP-1) that acutely increases endogenous growth hormone secretion via ghrelin receptor activation; used in clinical research for GH deficiency, muscle wasting, and anti‑aging studies.
Mechanism of Action
Agonist of the ghrelin receptor (GHSR) stimulating pituitary growth hormone release
Routes of Administration
Goals & Uses
- Study of GH secretory mechanismsBasic ScienceHigh
- Increase endogenous GH levelsEndocrineModerate
- IGF-1 elevationMetabolic / HormonalLow
- Growth hormone stimulationEndocrine / HormonalModerate
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- known hypersensitivity to peptideImmunologicModerate
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Acromegaly or gigantismEndocrineHigh
- Diabetic retinopathy or uncontrolled diabetesMetabolicModerate
Adverse Effects
- EdemaFluid BalanceRareSwelling from fluid retention
- Injection site reactionsLocalCommon
- Water retention / edemaFluid BalanceUncommon
- Elevated cortisol and prolactinEndocrineCommon
- Transient hyperglycemiaMetabolic/EndocrineUncommon
- Increased appetite / hungerGastrointestinal / MetabolicCommon
- GH-related paresthesiasNeurologicalUncommon
- DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady
- Increased appetiteMetabolicCommon
Drug Interactions
- InsulinLowMay increase risk of low blood sugar
- GlucocorticoidsModerate
- Somatostatin analogs (e.g., octreotide)Moderate
- Insulin / antidiabetic agentsModerate
Population Constraints
- PregnancyReproductive SafetyAbsolute
- Pediatric patientsAgeRelative
- Patients with pituitary tumorsOncologic / EndocrinologicAbsolute
- Elderly patientsAgeRelative
- Elderly with cardiovascular diseaseComorbidityRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization in European Union.
- United StatesInvestigationalInvestigational New Drug (IND) status; not FDA‑approved.
- United KingdomUnapprovedClassed as a research chemical; not licensed for clinical use.
Not approved by any regulatory authority (FDA, EMA, MHRA). Strictly a research compound used in preclinical and early clinical studies. Not scheduled as a controlled substance in most jurisdictions but is banned in sport by WADA.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Growth hormone-releasing peptide 1?
Synthetic hexapeptide (GHRP-1) that acutely increases endogenous growth hormone secretion via ghrelin receptor activation; used in clinical research for GH deficiency, muscle wasting, and anti‑aging studies.
What is Growth hormone-releasing peptide 1 used for?
Growth hormone-releasing peptide 1 is educationally associated with: Study of GH secretory mechanisms, Increase endogenous GH levels, IGF-1 elevation, Growth hormone stimulation. Educational only — not medical advice.
How is Growth hormone-releasing peptide 1 administered?
Recorded routes of administration: Intravenous, Oral, Subcutaneous.
What are the potential side effects of Growth hormone-releasing peptide 1?
Reported adverse effects include: Edema, Injection site reactions, Water retention / edema, Elevated cortisol and prolactin, Transient hyperglycemia, Increased appetite / hunger, GH-related paresthesias, Dizziness, Increased appetite. This list is not exhaustive — consult a qualified clinician.
Who should avoid Growth hormone-releasing peptide 1?
Recorded contraindications: Active malignancy, known hypersensitivity to peptide, Pregnancy, Acromegaly or gigantism, Diabetic retinopathy or uncontrolled diabetes. Consult a qualified clinician before use.